Latest 5-HT3 antagonist Stories
-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV -- LUGANO, Switzerland and WOODCLIFF LAKE, N.J., Oct. 13, 2014 /PRNewswire/ -- Helsinn Group and Eisai Inc.
CAMBRIDGE, England, October 7, 2014 /PRNewswire/ -- Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting
LUGANO, Switzerland and TOKYO, July 17, 2014 /PRNewswire/ -- Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the
LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the
WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, June 26, 2014 /PRNewswire/ -- Eisai Inc.
-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting -- WOODCLIFF LAKE, N.J.
DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bgdzzw/tesaros) has announced the addition of the "Tesaro's Rolapitant:
- Large; stout; burly.